Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 12, showing 5 Applications out of 60 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/19/07/01   IMPROVE-2
      chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2).    
Principal Investigator(s)
1. Hellen Cherono Barsosio
2. Simon Kariuki
Site(s) in Kenya
1. Ahero Sub-County Hospital (Kisumu county)
2. Rabuor Sub-County Hospital (Kisumu county)
3. Akala Sub-County Hospital (Siaya county)
 
Trial Status Recruiting
Protocol Date 17-05-2019
View

2.

ECCT/15/11/01   A5264
    A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy   versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of   Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)   
Principal Investigator(s)
1. Dr. Victor Otieno Mudhune
Site(s) in Kenya
1. KEMRI CDC (Kisumu county)
 
Trial Status Stopped
Protocol Date 04-08-2010
View

3.

ECCT/20/06/04   ANTICOV (01 COV)
    An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Mbagathi Infectious Disease Hospital (Nairobi City county)
2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county)
 
Trial Status Not yet recruiting
Protocol Date 16-06-2020
View

4.

ECCT/13/08/06  
    Management of myocardial injury After NoncArdiac surgGEry (MANAGE) Trial   
Principal Investigator(s)
1. GERALD OCHIENG\' YONGA
2. LEONARD MZEE NGUNGA
Site(s) in Kenya
Aga Khan University Hospital, Nairobi
 
Trial Status Recruiting
Protocol Date 30-11-2012
View

5.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
Trial Status Stopped
Protocol Date 14-11-2016
View